Online citations, reference lists, and bibliographies.
← Back to Search

Renal Changes Associated With Cyclosporine In Recent Type I Diabetes Mellitus

M. Rodier, J. Ribstein, C. Parer-Richard, A. Mimran
Published 1991 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The effects of cyclosporine A treatment on arterial pressure and renal function were assessed in 11 young patients with type I diabetes of short duration. Cyclosporine was started at 7.5 mg/kg/day, progressively decreased to 63 mg/kg/day at 6 months, and then continued at a lower dose (4.1 mg/kg/day) for an additional 3 months in patients in whom remission of insulin dependency was obtained (n=6). After 3 months of cyclosporine, a slight but significant increase in arterial pressure (+5.2±1.5 mm Hg), a rise in renal vascular resistance (—20%), a decrease in glomerular filtration rate (—25%), and a fall in filtration fraction were observed. Such changes were sustained after 6 and eventually 9 months of therapy. The decrease in glomerular filtration rate observed during cyclosporine treatment contrasted with the lack of change in simultaneously estimated creatinine clearance; in fact, the creatinine clearance/ glomerular filtration ratio increased from 1.07±0.05% to 1.33±0.09% within 3 months of cyclosporine therapy, thus suggesting an enhanced tubular secretion of creatinine. Plasma renin activity and urinary excretion of kallikrein decreased significantly (—50%), whereas plasma aldosterone concentration remained unaltered and plasma concentration of potassium increased during cyclosporine therapy. These changes were observed in the presence of a constant urinary excretion of sodium and potassium and a constant body weight All parameters returned to pretreatment values within 3 months after cessation of cyclosporine. These results indicate that cyclosporine given for 6-9 months at a moderate dose causes a deleterious but reversible effect on arterial pressure and renal function in young diabetic patients.
This paper references
10.1016/S0272-6386(89)80032-0
Renal vascular and thrombotic effects of cyclosporine.
G. Remuzzi (1989)
10.1016/S0140-6736(78)91970-0
CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS
R. Calne (1978)
Does cyclosporine inhibit renal synthesis of prostaglandins
D Adu (1985)
10.1172/JCI108749
Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake.
S. B. Levy (1977)
10.1161/01.RES.44.4.441
The renal kallikrein-kinin system.
N. Levinsky (1979)
10.1038/275144A0
Human urinary kallikrein converts inactive to active renin and is a possible physiological activator of renin
Jean E. Sealey (1978)
10.1038/KI.1985.196
Effect of cyclosporine administration on renal hemodynamics in conscious rats.
B. M. Murray (1985)
10.1038/KI.1990.182
Measurement of renal function in chronic renal disease.
A. Levey (1990)
Westre B: Side effects of cyclosporine A treatment in patients with rheumatoid arthritis
KJ Berg (1986)
10.1056/NEJM198803173181103
Factors associated with early remission of type I diabetes in children treated with cyclosporine.
P. Bougnères (1988)
10.1016/0140-6736(90)92630-Z
Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis
P. Tugwell (1990)
10.1007/978-1-4615-9543-4_59
The effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis.
J. Spragg (1989)
10.1038/KI.1988.92
Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells.
A. Kurtz (1988)
10.1056/NEJM198409133111103
Cyclosporine-associated chronic nephropathy.
B. Myers (1984)
Low-dose cyclosporine versus placebo in patients with rheumatoid arthritis
P Tugwell (1990)
10.1038/KI.1987.166
Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity.
E. Barros (1987)
10.1097/00007890-198707000-00027
Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function.
J. English (1987)
10.1172/JCI113982
Functional effects on glomerular hemodynamics of short-term chronic cyclosporine in male rats.
S. Thomson (1989)
The long - term course of cyclosporineassociated chronic nephropathy
G Remuzzi
The thromboxane synthetase inhibitor CGS 13080 improves renal allograft function in patients taking cyclosporine ( abstract )
JP Bantle (1990)
10.2337/diab.37.11.1574
Cyclosporin-Induced Remission of IDDM After Early Intervention: Association of 1 yr of Cyclosporin Treatment With Enhanced Insulin Secretion
(1988)
10.1056/NEJM199005173222003
A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis.
R. Wiesner (1990)
10.1016/S0140-6736(85)91902-6
REVERSIBILITY OF CYCLOSPORIN NEPHROTOXICITY AFTER THREE MONTHS' TREATMENT
J. R. Chapman (1985)
Methods for the determination of glandular kallikrein by means of a chromogenic substrate
E Amundsen (1979)
10.1001/ARCHINTE.1986.00360220169028
Renal interstitial fibrosis and vascular changes. Occurrence in patients with autoimmune diseases treated with cyclosporine.
K. Svenson (1986)
The renal kallikreinkinin system
J Spragg (1979)
10.1016/S0140-6736(86)91943-4
CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSET: Results of a Multicentre Double-blind Trial
G. Feutren (1986)
10.1001/ARCHINTE.1985.00360030153026
Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients.
J. Bantle (1985)
Use of cyclosporine in psoriasis
JD Bos (1989)
Side effects of cyclosporine A treatment in patients with rheumatoid arthritis
JD Bos (1986)
10.1016/S0140-6736(71)90382-5
Altered urinary kallikrein excretion in human hypertension.
H. Margolis (1971)
10.1073/PNAS.83.14.5345
Urinary kallikrein: a physiological regulator of epithelial Na+ absorption.
S. A. Lewis (1986)
The changing natural history of nephropathy in type I diabetes.
J. Wetzels (1986)
10.1038/KI.1990.139
Role of endothelin in cyclosporine-induced glomerular dysfunction.
V. Kon (1990)
Factors determining early remission of type I diabetes in children treated with cyclosporine
PF Bougneres (1988)
Does cyclosporine inhibit renal prostaglandin synthesis?
D. Adu (1985)
10.1016/0002-9343(84)90356-5
Side effects of systemic cyclosporine in patients not undergoing transplantation.
A. Palestine (1984)
Report of a WHO study group : Diabetes Mellitus
A Mimran (1985)
10.1056/NEJM197807272990402
Urinary kallikrein activity in the hypertension of renal parenchymal disease.
J. Mitas (1978)
10.1016/0002-9343(87)90497-9
Suppression of plasma renin activity by cyclosporine.
J. Bantle (1987)
Klotman PE: The thromboxane synthetase inhibitor CGS 13080 improves renal allograft function in patients taking cyclosporine (abstract)
TM Coffman (1990)
10.1016/S0140-6736(89)92941-3
USE OF CYCLOSPORIN IN PSORIASIS
J. Bos (1989)
10.1038/KI.1988.38
The long-term course of cyclosporine-associated chronic nephropathy.
B. Myers (1988)
10.1056/NEJM198112033052306
Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury.
H. Shulman (1981)
Microalbuminuria during an exercise test
A Orsetti (1988)
KEY WORDS • renal function • kallikrein • cyclosporine renin • diabetes
10.1038/KI.1986.125
Side effects of cyclosporin A treatment in patients with rheumatoid arthritis.
K. Berg (1986)
Perlroth M: Cyclosporine-associated chronic nephropathy
BD Myers (1984)
10.1007/978-1-4757-0926-1_9
Methods for the determination of glandular kallikrein by means of a chromogenic tripeptide substrate.
E. Amundsen (1979)
10.1056/NEJM198503073121004
Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes.
M. Wiseman (1985)
10.1159/000172879
The role of the renin-angiotensin system in the hormonal and renal responses to tilt in normal man.
A. Mimran (1983)
10.1159/000168001
Evolution of ciclosporin nephrotoxicity in patients treated for autoimmune uveitis.
H. Austin (1989)
10.1111/J.0954-6820.1980.TB09726.X
Renal concentrating capacity in long-term lithium treatment and after withdrawal of lithium.
G. Bucht (1980)
Glomerular hemodynamics and hormonal participation in cyclosporine nephrotoxicity. Kidney lnt 1987^32:19-32
EJG Barros (1987)
Side effects of cyclosporine A treatment in patients with rheumatoid arthritis
K J Berg (1986)
The Canadian-European Randomized Control Trial Group: Cyclosporin-induced remission of IDDM after early intervention
The thromboxane synthetase inhibitor CGS 13080 improves renal allograft function in patients taking cyclosporine (abstract)
T M Coffman (1990)



This paper is referenced by
10.1111/dth.12875
Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real‐world practice
J. H. Hong (2019)
10.1093/ILAR.45.3.278
Rat models of type 1 diabetes: genetics, environment, and autoimmunity.
J. Mordes (2004)
10.1093/OXFORDJOURNALS.NDT.A027408
Cyclosporin does not inhibit the tubular secretion of creatinine
Luuk B. Hilbrands (1996)
10.1097/00007890-199803150-00010
Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy.
G. Mourad (1998)
10.1097/01.TP.0000228888.31242.2B
POOR PREDICTION OF THE GLOMERULAR FILTRATION RATE USING CURRENT FORMULAS IN THE NOVO LIVER TRANSPLANT PATIENTS
J. Barkun (2006)
Svm~athetic Neural Mechanisms of CJyc~osporine-InducedHypertension
M. Sande (1997)
10.1097/01.tp.0000181112.02227.fc
Prediction of the Glomerular Filtration Rate using Equations in Kidney-Pancreas Transplant Patients Receiving Cimetidine
J. Schiff (2006)
10.1007/1-4020-2586-6_21
Calcineurin inhibitors and sirolimus
E. Burdmann (2003)
10.1007/978-0-387-84843-3_28
Nephrotoxicity of calcineurin and mTOR inhibitors
E. Burdmann (2008)
10.1006/CLIM.2000.4882
A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus.
B. Buckingham (2000)
10.1016/0895-7061(96)00288-9
Sympathetic neural mechanisms of cyclosporine-induced hypertension.
M. Sander (1996)
10.1007/1-4020-2586-6_2
Renal handling of drugs and xenobiotics
M. Broe (2003)
10.1006/CLIM.2001.5075
Translating data from animal models into methods for preventing human autoimmune diabetes mellitus: caveat emptor and primum non nocere.
D. Greiner (2001)
10.1093/ndt/11.5.833
Cyclosporin does not inhibit the tubular secretion of creatinine.
L. B. Hilbrands (1996)
Semantic Scholar Logo Some data provided by SemanticScholar